You are browsing the Hong Kong website, Regulated by Hong Kong SFC (CE number: BJA907). Investment is risky and you must be cautious when entering the market.
東曜藥業-B(01875.HK):醋酸甲地孕酮口服混懸液獲國家藥監局上市許可
格隆匯 05-13 12:14

格隆匯5月13日丨東曜藥業-B(01875.HK)宣佈,公司進口代理產品醋酸甲地孕酮口服混懸液(TOM218,於2014年在美國獲批上市)(“該產品”)獲得中國國家藥品監督管理局批准,可在中國大陸上市,用於治療獲得性免疫缺陷綜合徵(“AIDS”)的厭食症,以及AIDS及癌症患者惡病質引起的體重明顯減輕。該產品是從安成國際藥業股份有限公司進口,規格為125mg╱mL(150mL╱瓶)。公司擁有該產品在中國大陸、香港和澳門的獨家代理權,並擬使用商標名稱“美適亞®”。

醋酸甲地孕酮口服混懸液主要成分為醋酸甲地孕酮(一種半合成孕激素衍生物),能夠改善AIDS和癌症患者的惡病質狀態,有效改善食慾、食物攝入量、體重以及有時出現的噁心和嘔吐。口服混懸液相較於片劑藥品,可以緩解患者吞嚥不適感。該產品是目前中國大陸首個獲批上市的高濃度醋酸甲地孕酮口服混懸液,其明確了針對治療惡病質的口服劑量(推薦起始劑量為625mg╱天(5mL╱天))。高濃度醋酸甲地孕酮口服混懸液是在普通混懸劑工藝基礎上採用納米晶體工藝,提高患者治療依從性,更易被人體吸收。

根據世界衞生組織國際癌症研究機構(IARC)發佈的2020年全球最新癌症數據,2020年中國新發癌症病例457萬例,癌症死亡病例300萬例,而中國10大高發癌種中有6個常伴發惡病質,其中,胃食管及胰腺腫瘤惡病質的發生率超過65%。惡病質是導致腫瘤晚期患者高病死率和生存期縮短的一個重要因素。

Follow us
Find us on Facebook, Twitter , Instagram, and YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!
Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.
uSMART
Wealth Growth Made Easy
Open Account